Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy

Marion Delafosse¹, Eléonore Ponlot², Emmanuel Esteve¹, Louise Ghislain², Nicolas Hanset², Jean-Jacques Boffa¹, Catherine Johanet³, Karine Dahan⁴

Affiliations

¹ Sorbonne Université, UMR_S 1155, Paris, France; Institut National de la Santé et de la Recherche Médicale UMR_S 1155, Paris, France; Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France.
² Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France.
³ Department of Immunology, Saint Antoine Hospital, Paris, France.
⁴ Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France; ANDRA, B Braun, Paris, France. Electronic address: karine.dahan@yahoo.fr.

PMID: 33745532
DOI: 10.1016/j.kint.2020.12.029

Free article

Comment

Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy

Marion Delafosse et al. Kidney Int. 2021 Apr.

Free article

. 2021 Apr;99(4):1023-1024.

doi: 10.1016/j.kint.2020.12.029.

Authors

Marion Delafosse¹, Eléonore Ponlot², Emmanuel Esteve¹, Louise Ghislain², Nicolas Hanset², Jean-Jacques Boffa¹, Catherine Johanet³, Karine Dahan⁴

Affiliations

¹ Sorbonne Université, UMR_S 1155, Paris, France; Institut National de la Santé et de la Recherche Médicale UMR_S 1155, Paris, France; Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France.
² Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France.
³ Department of Immunology, Saint Antoine Hospital, Paris, France.
⁴ Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France; ANDRA, B Braun, Paris, France. Electronic address: karine.dahan@yahoo.fr.

PMID: 33745532
DOI: 10.1016/j.kint.2020.12.029

No abstract available

PubMed Disclaimer

Comment in

The authors reply.
Fernández-Juárez G, Rojas-Rivera J, Praga M. Fernández-Juárez G, et al. Kidney Int. 2021 Apr;99(4):1024-1025. doi: 10.1016/j.kint.2020.12.030. Kidney Int. 2021. PMID: 33745533 No abstract available.

Comment on

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M; STARMEN Investigators. Fernández-Juárez G, et al. Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7. Kidney Int. 2021. PMID: 33166580 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy

Affiliations

Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources